SGLT2 Plus GLP-1 Drug Beats SGLT2 Plus DPP-4 for Fatty Liver in Obese Mice

What the researchers found

High-fat diet versus control: liver triglycerides increased 82%, steatosis increased 850%, glucose intolerance increased 71%, insulin increased 98%, and insulin resistance increased 68%.

Both drug combinations improved all parameters compared to untreated obese mice:

- Empagliflozin + linagliptin: glucose intolerance -60%, insulin -61%, insulin resistance -46%, TAG -61%, steatosis -58%

- Empagliflozin + dulaglutide: glucose intolerance -71%, insulin -58%, insulin resistance -62%, TAG -61%, steatosis -82%

Principal component analysis clearly separated the groups: the GLP-1 combination was furthest from the disease group, while the DPP-4 combination fell between control and the GLP-1 group.

Why it matters

Fatty liver disease affects 25% of the global population and over half of people with type 2 diabetes. Single-drug treatment is often insufficient. This study compares two realistic combination strategies and shows the GLP-1 combination is clearly superior. This informs clinical decision-making about which drugs to combine for diabetes patients with fatty liver.

The numbers in context

- 40 mice (10 per group, 4 groups)

- Diet duration: 12 weeks high-fat

- Treatment duration: 3 weeks

- E+D vs HF: steatosis -82%, insulin resistance -62%, glucose intolerance -71%, TAG -61%

- E+L vs HF: steatosis -58%, insulin resistance -46%, glucose intolerance -60%, TAG -61%

- PCA placed E+D opposite from HF (disease group)

How the study worked

Male C57BL/6J mice (3 months old) were fed control or high-fat diet for 12 weeks. Then treated for 3 additional weeks: control, high-fat untreated, high-fat + empagliflozin + linagliptin, or high-fat + empagliflozin + dulaglutide. 10 mice per group. Outcomes: liver triglycerides, steatosis histology, glucose tolerance, insulin levels, and gene expression for metabolism and mitochondrial biogenesis.

Who was studied

40 male C57BL/6J mice on high-fat diet with metabolic dysfunction-associated steatotic liver disease

What this study cannot tell us

Tested in mice, not people. Only 3 weeks of treatment, which is short even for mice. The high-fat diet model creates MASLD but may not replicate all features of human disease. Dulaglutide and linagliptin were compared at standard doses, but dose equivalency across drug classes is difficult in animals. Gene expression changes were measured but functional validation was not performed.

How to read the evidence

Rated preliminary: animal study with only 3 weeks of treatment and 10 mice per group. Results need confirmation in longer studies and humans.

When this study was published

Published in 2024. Directly relevant to ongoing clinical discussions about optimal combination therapy for metabolic disease.

The bigger picture

Fatty liver disease affects 25% of the global population and over half of diabetes patients. This study supports combining an SGLT2 inhibitor with a GLP-1 drug rather than a DPP-4 inhibitor for the most liver benefit.

Questions still open

• Would semaglutide or tirzepatide paired with an SGLT2i produce even better results?
• Is 3 weeks of treatment enough to draw conclusions about chronic disease?

Common questions

Read the original research

Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD).

Fundamental & clinical pharmacology, 38(6), 1059-1068

Citation

Reis-Barbosa, Pedro H; Mandarim-de-Lacerda, Carlos A. (2024). Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD).. Fundamental & clinical pharmacology, 38(6), 1059-1068. https://doi.org/10.1111/fcp.13024